Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033020
First received: April 5, 2002
Last updated: April 13, 2010
Last verified: April 2010
  Purpose

The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.


Condition Intervention Phase
Substance-Related Disorders
Behavioral: Behavior Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • ASI
  • Opioid and cocaine use
  • AIDS risk behavior

Estimated Enrollment: 390
Study Start Date: April 2001
Study Completion Date: February 2003
Primary Completion Date: February 2003 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. The study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Recent admission to an opioid substitution (methadone maintenance) CTP. Completed at least 4 weeks of maintenance at time of study entry
  2. Evidence of cocaine or methamphetamine use Minimum of one documented positive urine within 2 weeks of study entry. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment

Exclusion Criteria:

  1. Unable to give informed consent (fails simple consent quiz)
  2. Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous gambling problems?
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033020

Locations
United States, California
Aegis Medical Systems, Inc.
Bakersfield, California, United States, 93301 4709
United States, District of Columbia
Oasis Clinic
Washington, District of Columbia, United States, 20002
United States, Maryland
Glenwood Life Counseling Center
Baltimore, Maryland, United States, 21212
United States, New York
Lower Eastside Service Center (LESC)
New York, New York, United States, 10007
Greenwich House, Inc.
New York, New York, United States, 10014
United States, Pennsylvania
ACT
Philadelphia, Pennsylvania, United States, 19141
United States, South Carolina
Charleston Center
Charleston, South Carolina, United States, 29403
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Maxine Stitzer, Ph.D. Johns Hopkins University
  More Information

No publications provided

Responsible Party: Maxine Stitzer, Ph.D., Johns Hopkins Bayview Medical Center
ClinicalTrials.gov Identifier: NCT00033020     History of Changes
Obsolete Identifiers: NCT00015418
Other Study ID Numbers: NIDA-CTN-0007-1
Study First Received: April 5, 2002
Last Updated: April 13, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methadone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Antitussive Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on September 14, 2014